KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 3.09%.

  • BioNTech SE's EBITDA Margin fell 39300.0% to 3.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.0%, marking a year-over-year increase of 17100.0%. This contributed to the annual value of 47.77% for FY2024, which is 658500.0% down from last year.
  • Latest data reveals that BioNTech SE reported EBITDA Margin of 3.09% as of Q3 2025, which was down 39300.0% from 192.14% recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBITDA Margin ranged from a high of 84.95% in Q4 2021 and a low of 750.74% during Q2 2024
  • In the last 5 years, BioNTech SE's EBITDA Margin had a median value of 35.58% in 2023 and averaged 59.14%.
  • As far as peak fluctuations go, BioNTech SE's EBITDA Margin tumbled by -4148400bps in 2024, and later skyrocketed by 5586000bps in 2025.
  • Quarter analysis of 5 years shows BioNTech SE's EBITDA Margin stood at 84.95% in 2021, then dropped by -9bps to 76.97% in 2022, then plummeted by -54bps to 35.58% in 2023, then tumbled by -65bps to 12.49% in 2024, then crashed by -125bps to 3.09% in 2025.
  • Its EBITDA Margin stands at 3.09% for Q3 2025, versus 192.14% for Q2 2025 and 292.18% for Q1 2025.